Recent News

• 08.06.2026 - Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• 08.03.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 07.30.2026 - Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
• 07.20.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 07.16.2026 - Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
• 07.14.2026 - New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
• 07.06.2026 - Definium Therapeutics Announces New Employee Inducement Grants
• 06.25.2026 - Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
• 06.24.2026 - Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
• 06.22.2026 - Definium Therapeutics, Inc. Announces Proposed Public Offering

Recent Filings

• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report
• 08.06.2026 - EX-99.1 EX-99.1
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.25.2026 - 144 Report of proposed sale of securities
• 06.25.2026 - 144 Report of proposed sale of securities